{"disease":{"id":"iga-monoclonal-gammopathy-of-undetermined-significance","name":"iga monoclonal gammopathy of undetermined significance"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07209371","title":"Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}